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http://dx.doi.org/10.1016/j.jmii.2013Background: Enterobacter species has emerged as an important pathogen of nosocomial
bacteremia. The purpose of this study is to review the clinical characteristics of bacteremia
in pediatric patients.
Materials and methods: We reviewed retrospectively the medical records of patients (under
the age of 18 years) having Enterobacter bacteremia who were treated at Taipei the Veterans
General Hospital from January 2001 to June 2011.
Results: In total, 853 positive blood cultures were obtained from 620 patients during the study
period. Among them, 96 episodes of Enterobacter bacteremia were found in 83 patients, ac-
counting for 11.3% of all bacteremia. Eighty-two cases (98.8%) were nosocomial infections.
Most of the cases were neonates (62 cases, 74.7%) and premature infants (51 cases, 61.5%).
The common sources of bacteremia were the respiratory tract (53.0%), followed by intravas-
cular catheter (10.8%), multiple sources (10.8%), and the gastrointestinal tract (8.4%). The
overall case fatality rate was 18.1%, with the highest rate being reported among premature
infants. The factors responsible for the deaths were leukocytosis and a higher median number
of underlying diseases.
Conclusion: Based on the findings of the present study, it can be concluded that Enterobacter
species are probably an important pathogen of nosocomial bacteremia in premature neonates.
The number of underlying diseases should be considered a major factor influencing the prog-
nosis.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan.
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382 H.-L. Chen et al.Introduction originated from the lungs when a ventilator was used for aNosocomial bloodstream infections are important causes of
morbidity and mortality worldwide. Enterobacter species,
which are the normal members of the flora of the gastro-
intestinal tract, are significant pathogens for a variety of
infections, such as pneumonia, urinary tract infections,
wound infections, and bacteremia, especially in nosocomial
infections.1e3 In healthy children, Enterobacter species
rarely cause any disease; however, in patients with un-
derlying diseases, especially in premature patients, they
are frequent pathogens involved in bacteremia.3e5 Several
risk factors of Enterobacter bacteremia are known, such as
gastrointestinal disease, life-threatening infections, ma-
lignancies, prematurity, use of a central venous catheter,
ventriculostomy, use of a ventriculoperitoneal shunt cath-
eter, prolonged antibiotic therapy, parenteral nutrition,
and immunosuppressive therapy.6 According to a large-
scale survey conducted in the USA, Enterobacter cloacae
accounted for 3.9% of all nosocomial bloodstream in-
fections.4 At the same time, a significant increase was
observed in the antimicrobial resistance rates of E. cloacae.
We conducted a retrospective study in order to review the
clinical characteristics and antimicrobial susceptibility of
Enterobacter bacteremia in pediatric patients.
Materials and methods
We reviewed retrospectively the medical records of pa-
tients under the age of 18 years, whose blood cultures
yielded Enterobacter species, treated at the Taipei Veter-
ans General Hospital between January 2001 and June 2011.
Data were collected on age, sex, abnormal clinical findings
[fever, poor activity, leukocytosis, leukopenia, and high C-
reactive protein (CRP) level], underlying illness, and type of
infection. The presence of the following comorbid condi-
tions was also documented: parenteral nutrition, cortico-
steroid use, immunosuppressant use, and invasive
procedures.
Definitions
Enterobacter bacteremia was defined as the presence of
Enterobacter species in one or more positive blood cultures
collected during the hospitalization of these patients with
corresponding clinical conditions. Only the first episode of
Enterobacter bacteremia in each patient was considered as
“one patient”. Nosocomial infection was defined as an
infection occurring after 72 hours of admission. Otherwise,
bacteremia was considered to be community acquired.
Polymicrobial bacteremia was defined as the isolation of
multiple pathogens from the same culture (the same bottle
of blood culture) or from different cultures (different bot-
tles) but at the same time.
The source of infection was determined as one of the
following: respiratory tract, intestinal, biliary tract, urinary
tract, surgical wounds, intravascular catheter, or multiple
or unknown sources, based on clinical signs and symptoms
(e.g., fever, leukocytosis, leukopenia, poor activity, and
high CRP level) of infection and organisms cultured fromthese possible sources. Bacteremia was considered to have
prolonged time or radiologic evidence of new-onset or
progressing pneumonia was found with concomitant isola-
tion of Enterobacter species from blood or sputum.
Bacteremia of unknown origin was defined as bacteremia
for which there was no documented distal source.
Empirical antibiotic treatment was considered appro-
priate when all isolated pathogens were susceptible to at
least one of the administered agents and it was administered
prior to the time of positive blood culture. However,
empirical therapy was considered inappropriate when the
isolate was nonsusceptible to the antimicrobial agents(s)
administered or the patients were not prescribed antimi-
crobial agents on the day of the onset of bacteremia.7 Re-
covery was defined as improvements in patients’ clinical
condition, such as becoming afebrile and having stable vital
signs after the initiation of antibiotic therapy. Morbidity was
considered when the patients had long time sequels which
were directly related to bacteremia, despite appropriate
antibiotic treatments. The case fatality rate was defined as
the number of deaths among patients with bacteremia.
Death was not considered directly because of other condi-
tions being apparently documented as the cause of death;
otherwise, the death was attributable to the bacteremia.
Nonparametric data were expressed as median and range.
Microbiology
Blood samples of around 0.5e1.0 mL were collected under
sterile conditions from peripheral punctures and injected
directly into Baxtar blood culture bottles. These bottles
were then incubated in BACTEC 9240, which is designed for
the rapid detection of bacteria and fungi in clinical cultures
of blood (Becton Dickinson Diagnostic Instrument Systems,
Sparks, MD, USA), at 35.5C. Antimicrobial susceptibility
tests were carried out using the MicroScan AutoSCAN-4 data
management system (Dade MicroScan Inc., West Sacra-
mento, CA, USA).
Statistical analysis
Univariate analysis was performed to identify the possible
risk factors associated with death attributable to Enter-
obacter bacteremia. The ManneWhitney U test, indepen-
dent samples t test, and Fisher’s exact test were used as
appropriate. Statistical analysis was performed using IBM
SPSS version 19 (SPSS Inc., Chicago, IL, USA). A p value of
<0.05 was considered statistically significant.
Results
During the 10-year retrospective study period, 853 positive
blood cultures were obtained from 620 pediatric patients.
The most common pathogens of bacteremia were yeast,
Staphylococcus aureus, and Staphylococcus epidermidis;
Enterobacter ranked fourth, accounting for 11.3% of all
types of bacteremia. E. cloacae was the most common
species, accounting for 78 episodes (81.3%); followed by
Enterobacter aerogenes, for 11 episodes (11.5%); Enter-
obacter sakazakii, for four episodes (4.2%); and
Figure 1. Yearly distribution (number of episodes) of
Enterobacter species in all bacteremic pathogens during the
10-year study period.
Enterobacter bacteremia 383Enterobacter agglomerans, for three episodes (3.1%).
Thirteen patients (15.7%) had two distinct episodes of
bacteremia. The rates of Enterobacter bacteremia in all
bacteremia during 2001e2010 were 4.3% (2001), 8% (2002),Table 1 Clinical characteristics of patients with Enterobacter b
Parameters
Age 0e1 m
>1e6
>6 m
>1e6
>6e1
>12e
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Fema
Length of stay (d)a NICU/
Hospi
Onset of bacteremia, days after admission
Abnormal clinical findings Fever
Poor
Leuko
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Comorbid conditions Intrav
Invas
Cortic
Admission diagnosis Prem
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Infection type Nosoc
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Empirical antibiotic treatment Appro
Inapp
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a Median (range).
b Central venous catheter, chest tube, cystostomy, drainage tube,
bilical vein/arterial line (1 patient had 1 or more procedures).
c Neurological sequel (1 patient), endocarditis (1 patient), and resp
CHDZ congenital heart disease; CRPZ C-reactive protein; NICUZ n11.8% (2003), 20.9% (2004), 18.2% (2005), 9.5% (2006),
16.9% (2007), 6.6% (2008), 9.1% (2009), and 7.6% (2010). We
found a peak incidence of Enterobacter bacteremia in
2004, with 19 cases (23 episodes); the yearly distribution of
Enterobacter species in all bacteremic pathogens during
the 10-years study period is shown in Fig. 1. The clinical
characteristics of patients with bacteremia are given in
Table 1. There were 48 male and 35 female patients; the
majority of patients were neonates (74.7%). Nosocomial
infection was reported in 82 cases (98.8%), and one case
(1.2%) was community acquired. Polymicrobial bacteremia
(2 or 3 microorganisms) occurred in two cases (2.4%):
Enterococcus faecalis (1), Escherichia coli (1), and E. aer-
ogenes (1). Nearly all the patients (98.8%) received appro-
priate antibiotic treatment. All patients had major
underlying conditions, with most of them having more than
one condition (Table 2). The most prominent underlying
condition in patients with Enterobacter bacteremia was
prematurity (51 cases, 61.4%), and the most prominent
predisposing factors were central venous catheter use (75
cases, 90.4%) and prolonged antibiotic therapy (77 cases,
92.8%).acteremia
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17 (1e164)a
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activity 21 (23.5)
cytosis (>11,000 cells/mm3) 58 (69.9)
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enous nutrition 52 (62.7)
ive procedureb 61 (73.5)
osteroid or cytotoxic therapy 12 (14.5)
aturity 51 (61.5)
10 (12.1)
s 12 (14.5)
llaneous 10 (12.1)
omial infection 82 (98.8)
unity acquired 1 (1.2)
priate 82 (98.8)
ropriate 1 (1.2)
ery 65 (78.3)
dityc 3 (3.6)
fatality 15 (18.1)
endotracheal intubation, pericardial tube, rectal tube, and um-
iratory failure (1 patient).
eonatal intensive care unit; PICUZ pediatric intensive care unit.
Table 2 Major underlying conditions (patients may have more than one underlying condition)
Condition Number of patients (%)
Underlying illness Prematurity 51 (61.4)
Gastrointestinal disease 40 (48.2)
Malignancy a 12 (14.5)
Other life-threatening infection b 21 (25.3)
Others c 42 (50.6)
Predisposing factor Central venous catheter 75 (90.4)
Prolonged antibiotic therapy 77 (92.8)
Prolonged parenteral nutrition 53 (63.9)
Immunosuppressive therapy 13 (15.7)
Ventriculostomy or ventriculoperitoneal shunt catheter 4 (4.82)
a Malignant brain tumor (2 patients), hematological malignancy (7 patients), and bone tumor (3 patients).
b Postoperative infection (17 patients) and central nervous system infection (4 patients).
c Congenital heart disease (10 patients), congenital anomalies (12 patients), pneumonia (8 patients), premature rupture of membrane
(7 patients), respiratory failure (3 patients), asphyxia (1 patient), and herpetic gingivostomatitis (1 patient).
384 H.-L. Chen et al.The respiratory tract (53.0%), intravascular catheter
(10.8%), multiple sources (10.8%), gastrointestinal tract
(8.4%), and genitourinary tract (8.4%) were the major
sources of bacteremia. Other sources included surgical
wounds (2.4%) and the biliary tract (1.2%). During the study
period, most of the patients had two to three episodes of
bacteremia caused by other microorganisms.
In this study, the overall case fatality rate was 18.1%
(15/83). Death was attributed to E. cloacae bacteremia in
14 cases (93.3%) and E. aerogenes bacteremia in one case
(6.7%). The prognostic factors, including clinical and labo-
ratory factors, potentially related to deaths due to
bacteremia in patients with Enterobacter species infection
are shown in Table 3. Factors that correlated significantly
with a poor prognosis in the univariate analysis were
leukocytosis >11,000 cells/mm3 (p Z 0.030) and a higher
median number of underlying diseases (p < 0.001).
Antimicrobial susceptibility to Enterobacter species
isolated from blood culture is summarized in Table 4. Dur-
ing the study period, E. cloacae was found to be resistant to
ampicillin/sulbactam (100%), ampicillin (96.7%), cefazolin
(96.5%), ceftriaxone (94.2%), cefuroxime (84.3%), piper-
acillin (73.0%), and ceftazidime (57.4%). No isolate was
resistant to cefepime, ciprofloxacin, and meropenem. FromTable 3 Prognostic factors associated with death in bacteremi
Variable
Age (1 mo)
Sex
Male
Female
Length of hospital stay >1 wk
Median number of underlying illnesses (interquartile range)
Sepsis (fever >39C, poor activity)
Leukocytosis (>11,000 cells/mm3)
Leukopenia (<4000 cells/mm3)
C-reactive protein >10 mg/dL
Inappropriate empirical therapy
Polymicrobial bacteremia2001 to 2005, three of 44 (6.8%) isolates were resistant to
amikacin, 15 of 41 (36.6%) to trimethoprim/sulfamethoxa-
zole, 14 of 30 (46.7%) to piperacillin, 25 of 42 (59.5%) to
tobramycin, and 35 of 43 (81.4%) to cefuroxime. However,
from 2006 to 2011, rates of resistance to cefuroxime
increased to 88.9% (p Z 0.857), piperacillin to 84.2%
(p Z 0.247), trimethoprim/sulfamethoxazole to 77.8%
(p Z 0.097), tobramycin to 66.7% (pZ 0.843), and amakin
to 11.1% (p Z 0.672) (Fig. 2).Discussion
The incidence of nosocomial Enterobacter bacteremia is
gradually increasing7 and was reported to account for 10.9%
of nosocomial infections in a study from Taiwan conducted
in 1999.8 Bonadio et al9 reported that E. cloacae bacter-
emia was a relatively rare infection in pediatric population
and the rate of isolation of this organism relative to all
positive blood cultures was 0.6%. Other studies reported
that Enterobacter bacteremia accounted for 5e6% of all
bacteremia6 and 8.7% cases of neonatal sepsis.10 In our
recent study, Enterobacter bacteremia was found to ac-
count for 11.3% of all bacteremia; based on the findings,a due to Enterobacter species
Survival
n Z 68 (%)
Death attributed to bacteremia
n Z 15 (%)
p
49 (72.1) 13 (86.7) 0.244
0.182
37 (54.7) 11 (73.3)
31 (45.6) 4 (26.7)
66 (97.1) 15 (100) 0.504
2 (1.0) 3 (1.0) <0.001
50 (73.5) 12 (80) 0.604
44 (66.2) 14 (93.3) 0.030
18 (26.5) 1 (6.7) 0.100
20 (29.4) 6 (40) 0.426
1 (1.5) 0 (0) 0.639
1 (1.5) 1 (6.7) 0.238
Table 4 Antimicrobial susceptibility of Enterobacter organisms
Antimicrobial agents E. cloacae E. sakazakii E. aerogenes
No.
tested
Susceptible No.
tested
Susceptible No.
tested
Susceptible
No. % No. % No. %
Ampicillin 61 1 1.6 4 0 0 10 0 0
Ampicillin/sulbactam 9 0 0 4 0 0
Piperacillin 63 17 27.0 4 0 0 10 0 0
Gentamicin 70 23 32.9 4 0 0 10 0 0
Amikacin 71 53 74.6 4 4 100 10 10 100
Cefazolin 57 1 1.8 4 0 0 10 0 0
Cefuroxime 70 7 10 4 0 0 10 0 0
Ceftazidime 68 23 33.8 4 0 0 10 0 0
Ceftriaxone 69 28 40.6 4 0 0 10 0 0
Imipenem 52 50 96.2 4 4 100 10 10 100
Meropenem 37 37 100
Ciprofloxacin 7 7 100
Trimethoprim/sulfamethoxazole 68 22 32.4 4 0 0 10 0 0
Tobramycin 69 24 34.8
Cefepime 1 1 100
Enterobacter bacteremia 385our study suggests that Enterobacter is becoming a more
frequent cause of bacteremia in pediatric patients.
Enterobacter sepsis is mostly a nosocomial infection,11
and there is strong evidence to suggest that alterations in
the gastrointestinal bacterial flora of hospitalized patients
lead to the selection of virulent and frequently resistant
strains of Enterobacter species, with a subsequent risk of
infection.12,13 Several other studies have indicated that
Enterobacter infections are particularly severe in children
younger than 18 months.14e16 Our study involved mostly ne-
onates (74.7%) and premature infants (61.5%). Hervas et al10
reported that the predisposing factors for nosocomial in-
fections in patients of a neonatal intensive care unit (NICU)
were mainly prematurity (57.7%) and respiratory problems
(37.7%), which are similar to our results. All the patients in
our study had an underlying illness and/or predisposing fac-
tors that are known to contribute to colonization of Enter-
obacter species, and our case fatality rate was 18.1%, in
comparison with 21e24% reported in other series.6,14,17
The US National Nosocomial Infections Surveillance Sys-
tem revealed that the common sources of E. cloacaeFigure 2. Resistance of Enterobacter isolates to selected
antimicrobials in 2001e2005 and 2006e2011.bacteremia were (in the descending order) unknown (pri-
mary bacteremia), respiratory tract, genitourinary tract,
intravascular catheter, wounds/surgery, gastrointestinal
tract/abdomen, skin/soft tissue, biliary tract, and burns.18
Another study reported that the most common portal of
entry for pathogens was the gastrointestinal tract (39%),19
but in our study, the most common source of infection
was the respiratory tract (53.01%), which may be related to
the invasive medical interventions and respiratory prob-
lems associated with prematurity. In our study, no signifi-
cant difference in mortality was noted among patients who
acquired bacteremia from different routes. We reported 82
cases (98.8%) of nosocomial Enterobacter bacteremia,
which was higher than the rate reported in pediatric pa-
tients (57e67%)9,14 and in adult populations (72e84%).20e24
Many factors favor the development of nosocomial in-
fections in neonates. Nosocomial patients are always
associated with an immunocompromised status, long-term
hospitalization, and invasive procedures or surgeries. A
substantial percentage of the patients were premature in-
fants who had complications, especially respiratory distress
and gastrointestinal diseases; underwent an invasive pro-
cedure (e.g., intubation or central venous catheter);
received parenteral nutrition and prolonged antibiotics;
and had a prolonged hospital stay.
In the present study, the most common underlying dis-
ease associated with Enterobacter bacteremia was pre-
maturity, followed by gastrointestinal disease. Although no
single underlying disease was associated with mortality, a
higher median number of underlying diseases was corre-
lated significantly with poor prognosis in bacteremic pa-
tients. The number of underlying diseases should be
considered as a major factor influencing the prognosis.
During the years 1992e1998, an increase in the resistance
rate of Enterobacter to third-generation cephalosporins
(from 22.2% to 59.2%) was observed in one study, which was
related to the use of cefotaxime for empirical treatment of
nosocomial infections in the NICU.25 E. cloacae isolates in
386 H.-L. Chen et al.this study had high rates of resistance to cefuroxime (84.3%)
and ceftriaxone (94.2%), which was similar to other study
results.26 Enterobacter readily develops resistance to sec-
ond- and third-generation cephalosporins, and this is asso-
ciated with the previous use of extended-spectrum
cephalosporins.20,25 We observed a relatively high resis-
tance rate of Enterobacter to second- and third-generation
cephalosporins and to extended-spectrum penicillins; how-
ever, the lack of statistical significance may be attributed to
the small number of cases. Widespread antimicrobial resis-
tance now exists among Enterobacter strains, which has
been reported to affect the clinical outcome of affected
patients in some studies.20,25,27 In the past decade, many
studies have reported outbreaks caused by Enterobacter in
neonatal settings, especially by multiple drug-resistant
strains.10,19,28 However, there are also studies suggesting
that the emergence of resistant organisms and the use of
corresponding antibiotics may be coincidental.29
In conclusion, Enterobacter species are emerging noso-
comial pathogens with increasing antimicrobial resistance.
Our study includes a review of clinical characteristics of
bacteremia in pediatric patients. Leukocytosis and a high
median number of underlying diseases are significantly
associated with death attributable to bacteremia. Inap-
propriate use of antibiotics and polymicrobials are not
associated with mortality. The limitations of our study are
its retrospective nature and small sample size. Therefore,
additional studies are needed to explain further the char-
acteristics of Enterobacter bacteremia.References
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